Plant Name: Aloe microstigma
Taxonomic Information:
Plant ID: NPO2466
Plant Latin Name: Aloe microstigma
Taxonomy Genus: Aloe
Taxonomy Family: Asphodelaceae
Plant External Links:
NCBI TaxonomyDB:
1128801
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; HTR2A; HTR1A; DRD1; DRD2; | |
| OPRM1; OPRD1; | |
| PDE10A; | |
| PDE3A; | |
| CA2; | |
| SENP6; | |
| THPO; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | SENP6 | Sentrin-specific protease 6 | Q9GZR1 | CHEMBL1741215 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Peptide receptor (family A GPCR) | OPRM1 | Mu opioid receptor | P35372 | CHEMBL233 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Phosphodiesterase 10 | PDE10A | Phosphodiesterase 10A | Q9Y233 | CHEMBL4409 |
| Phosphodiesterase 3 | PDE3A | Phosphodiesterase 3A | Q14432 | CHEMBL241 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 6.228E-08 | 8.476E-05 | HTR1A, HTR2A, HTR7 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 4.285E-07 | 4.443E-04 | DRD1, DRD2, HTR2A |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 7.593E-07 | 6.124E-04 | HTR1A, HTR2A, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 7.593E-07 | 6.124E-04 | HTR1A, HTR2A, HTR7 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 1.368E-06 | 1.027E-03 | HTR1A, HTR2A, HTR7 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 1.681E-06 | 1.220E-03 | DRD1, DRD2, HTR2A |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 2.091E-06 | 1.339E-03 | DRD1, HTR1A, HTR2A, HTR7 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 3.374E-06 | 1.853E-03 | HTR1A, HTR7 |
| BP | GO:0050896; response to stimulus | GO:0009628; response to abiotic stimulus | 4.531E-06 | 2.349E-03 | CA2, DRD1, DRD2, HTR2A, LMNA, OPRD1, OPRM1 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 5.621E-06 | 2.782E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.428E-06 | 3.670E-03 | CYP2C19, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.312E-05 | 5.290E-03 | DRD2, HTR2A, OPRM1, THPO |
| BP | GO:0007610; behavior | GO:0050795; regulation of behavior | 1.534E-05 | 5.704E-03 | DRD2, HTR1A, HTR2A |
| BP | GO:0009987; cellular process | GO:0038003; opioid receptor signaling pathway | 1.572E-05 | 5.704E-03 | OPRD1, OPRM1 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 1.572E-05 | 5.704E-03 | DRD1, DRD2 |
| MF | GO:0060089; molecular transducer activity | GO:0004985; opioid receptor activity | 1.572E-05 | 5.704E-03 | OPRD1, OPRM1 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.625E-05 | 5.800E-03 | CA2, DRD1, DRD2, HTR2A |
| BP | GO:0009987; cellular process | GO:0007191; adenylate cyclase-activating dopamine receptor signaling pathway | 2.524E-05 | 8.026E-03 | DRD1, OPRM1 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 2.524E-05 | 8.026E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0018958; phenol-containing compound metabolic process | 2.783E-05 | 8.302E-03 | DRD1, DRD2, HTR1A |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 3.083E-05 | 8.834E-03 | DRD1, DRD2 |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 3.461E-05 | 9.663E-03 | CA2, DRD2, HTR2A, OPRM1, PDE3A, THPO |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 3.698E-05 | 9.887E-03 | DRD1, DRD2 |
| MF | GO:0060089; molecular transducer activity | GO:0004952; dopamine neurotransmitter receptor activity | 3.698E-05 | 9.887E-03 | DRD1, DRD2 |
| CC | GO:0044464; cell part | GO:0030424; axon | 3.723E-05 | 9.887E-03 | CA2, DRD2, HTR2A, OPRM1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 5.305E-10 | 2.069E-08 | OPRD1, HTR7, HTR1A, OPRM1, HTR2A, DRD1, DRD2 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.445E-08 | 2.819E-07 | HTR7, CYP2D6, HTR1A, HTR2A, CYP2C19 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05032 | Morphine addiction | 5.268E-07 | 6.848E-06 | PDE10A, PDE3A, OPRM1, DRD1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.191E-05 | 1.162E-04 | HTR1A, PDE3A, DRD1, DRD2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 3.605E-05 | 2.812E-04 | HTR2A, DRD1, DRD2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 3.012E-04 | 1.958E-03 | HTR7, HTR2A, DRD1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 6.050E-04 | 3.371E-03 | DRD1, DRD2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.196E-03 | 5.833E-03 | CYP2D6, CYP2C19 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; HTR1A; |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1; |
| NA: NA | Schizoaffective disorder | NA | PDE10A; HTR1A; |
| NA: NA | Vomiting | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| NA: NA | Episode | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | OPRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Mild pain | R52, G89 | OPRM1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | OPRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; HTR1A; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1; |
| NA: NA | Itching | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | OPRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | General anesthesia | R20.0 | OPRM1; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | OPRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; HTR1A; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Headache | G43-G44, R51 | OPRM1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | OPRM1; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; OPRM1; HTR2A; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | OPRM1; DRD2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; OPRD1; HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Systemic pain | R52, G89 | OPRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Analgesia | R52, G89 | OPRM1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRM1; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| K00-K95: Diseases of the digestive system | Opioid-induced constipation | K59.0 | OPRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; OPRD1; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Narcotic depression | F19.20, F32 | OPRM1; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Movement disorder | R25 | OPRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD1; DRD2; HTR2A; PDE10A; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe acute pain | R52, G89 | OPRM1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| NA: NA | Addiction | NA | HTR2A; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | DRD2; HTR2A; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| NA: NA | Social phobia | NA | HTR1A; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; HTR1A; |
| K00-K95: Diseases of the digestive system | Constipation | K59.0 | OPRM1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | OPRM1; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| NA: NA | False perceptions | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | OPRM1; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | OPRM1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR2A; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| NA: NA | Hyperaemia | NA | DRD2; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRM1; OPRD1; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRM1; HTR7; DRD2; OPRD1; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | OPRM1; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; PDE10A; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; HTR1A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRM1; DRD1; DRD2; OPRD1; HTR1A; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
